Newly diagnosed PAH patients on triple therapy have fewer hospitalizations vs. double therapy

A study looked at about 3000 pulmonary arterial hypertension patients and found that people who added selexipag to double therapy (an endothelin receptor agonist like ambrisentan, macitentan, or bosentan and a phosphodiesterase type 5 inhibitor like sildenafil or tadalafil) within six months had a lower risk of hospitalization and disease progression. They suggest that delaying the start of triple therapy contributes to worse outcomes.

Read the JAMA Network Open paper